😎 Sommerzeit, Hammer-Deals! Bei InvestingPro winken jetzt bis zu 50% Rabatt auf KI-Aktien-TippsJETZT ZUGREIFEN

DGAP-News: OXIS International Announces Joint Venture With Global Leading Digital Marketing Firm engage:BDR to Launch New EGT(TM) Based Health and Nutrition Product Line in April (deutsch)

Veröffentlicht am 17.04.2012, 08:30
OXIS International Announces Joint Venture With Global Leading Digital Marketing Firm engage:BDR to Launch New EGT(TM) Based Health and Nutrition Product Line in April

Oxis International Inc.

17.04.2012 08:30

---------------------------------------------------------------------------

Global Online Digital Campaign Reaching Target Audience of 109 Million Expected

to Drive Significant Revenue

BEVERLY HILLS, Calif., 2012-04-17 08:30 CEST (GLOBE NEWSWIRE) --

OXIS International, Inc., (OTCBB:OXIS); (Paris:OXI) today announced its joint

venture with engage:BDR, a leading full-service digital advertising and

marketing agency, to launch its new antioxidant L-Ergothioneine (EGT(tm)) based

health and nutrition product line.

OXIS International is developing and manufacturing their proprietary EGT line

of products. engage:BDR will promote, market and create a full digital

advertising campaign for the line of health and nutrition products, reaching a

targeted audience of more than 109 million through its engage:BDR advertising

network and through mobile and video advertising.

'We have an unprecedented opportunity to introduce our proprietary EGT(tm) based

products direct to consumers with the help of our partners at engage:BDR,' said

David Saloff, Chairman and CEO, OXIS International. 'Their outstanding track

record executing direct-to-consumer products and ability to deliver our product

message to a very targeted audience will make for a very successful launch.'

EGT is referred to as the 'intelligent antioxidant' because it is the only

anti-oxidant having a dedicated transport mechanism in the body to deliver it

through the cell membrane and even into the mitochondria, the energy producing

area of the cell. Additionally, when other powerful antioxidants are also

present, the body preferentially utilizes ergothioneine. OXIS holds the

exclusive patent to manufacture EGT, which has received full GRAS (safety)

approval.

'OXIS International has illustrated tremendous expertise in product development

and manufacturing in creating the EGT product line which we're extremely

excited to deliver to the market,' said Ted Dhanik, president, engage:BDR.

'Engage:BDR delivers an end-to-end digital advertising services for companies

like OXIS to reach their audience, leveraging our extensive reach and

proprietary methodologies which we feel will boost their bottom line.'

ErgoFlex(tm) will be the first EGT-based product to launch. ErgoFlex is a unique,

clinically-proven dietary supplement for the rapid relief of joint pain and

improved mobility. ErgoFlex was successfully test marketed in a direct mail

campaign by OXIS in 2011. Additional products are expected to launch in early

summer.

About engage:BDR

engage:BDR provides advertisers cutting-edge marketing solutions, advanced

technology and custom programming by integrating display, video and branded

entertainment into a single network. Whether it's driving qualified traffic and

leads or building awareness and engagement, engage:BDR is committed to

providing innovative solutions to reach consumers and deliver the highest

quality results to their partners. Headquartered in Los Angeles, engage:BDR

attracts a list of top name partners and customers including Ask.com, Bose, CBS

Interactive, eHarmony, Live Nation, Sony Pictures among others.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research,

diagnose, treat and prevent diseases of oxidative stress/inflammation

associated with damage from free radical and reactive oxygen species (ROS). The

company holds the rights to several therapeutic classes of compounds in the

area of oxidative stress, including EGT(tm) (99% pure L-ergothioneine), known as

the intelligent antioxidant.

CONTACT: David Saloff

424-248 2311

David@Oxis.com

www.oxis.com

News Source: NASDAQ OMX

17.04.2012 Dissemination of a Corporate News, transmitted by DGAP -

a company of EquityStory AG.

The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------



Language: English

Company: Oxis International Inc.





United States

Phone:

Fax:

E-mail:

Internet:

ISIN: US6918294025

WKN:



End of Announcement DGAP News-Service



---------------------------------------------------------------------------

Aktuelle Kommentare

Installieren Sie unsere App
Risikohinweis: Beim Handel mit Finanzinstrumenten und/oder Kryptowährungen bestehen erhebliche Risiken, die zum vollständigen oder teilweisen Verlust Ihres investierten Kapitals führen können. Die Kurse von Kryptowährungen unterliegen extremen Schwankungen und können durch externe Einflüsse wie finanzielle, regulatorische oder politische Ereignisse beeinflusst werden. Durch den Einsatz von Margin-Trading wird das finanzielle Risiko erhöht.
Vor Beginn des Handels mit Finanzinstrumenten und/oder Kryptowährungen ist es wichtig, die damit verbundenen Risiken vollständig zu verstehen. Es wird empfohlen, sich gegebenenfalls von einer unabhängigen und sachkundigen Person oder Institution beraten zu lassen.
Fusion Media weist darauf hin, dass die auf dieser Website bereitgestellten Kurse und Daten möglicherweise nicht in Echtzeit oder vollständig genau sind. Diese Informationen werden nicht unbedingt von Börsen, sondern von Market Makern zur Verfügung gestellt, was bedeutet, dass sie indikativ und nicht für Handelszwecke geeignet sein können. Fusion Media und andere Datenanbieter übernehmen daher keine Verantwortung für Handelsverluste, die durch die Verwendung dieser Daten entstehen können.
Die Nutzung, Speicherung, Vervielfältigung, Anzeige, Änderung, Übertragung oder Verbreitung der auf dieser Website enthaltenen Daten ohne vorherige schriftliche Zustimmung von Fusion Media und/oder des Datenproviders ist untersagt. Alle Rechte am geistigen Eigentum liegen bei den Anbietern und/oder der Börse, die die Daten auf dieser Website bereitstellen.
Fusion Media kann von Werbetreibenden auf der Website aufgrund Ihrer Interaktion mit Anzeigen oder Werbetreibenden vergütet werden.
Im Falle von Auslegungsunterschieden zwischen der englischen und der deutschen Version dieser Vereinbarung ist die englische Version maßgeblich.
© 2007-2024 - Fusion Media Limited. Alle Rechte vorbehalten.